- Home
- GWH vs CELU Comparison
GWH vs CELU Comparison
Compare GWH & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- CELU
- Stock Information
- Founded
- GWH 2011
- CELU 2016
- Country
- GWH United States
- CELU United States
- Employees
- GWH N/A
- CELU N/A
- Industry
- GWH Industrial Machinery/Components
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- CELU Health Care
- Exchange
- GWH Nasdaq
- CELU Nasdaq
- Market Cap
- GWH 39.6M
- CELU 42.2M
- IPO Year
- GWH N/A
- CELU N/A
- Fundamental
- Price
- GWH $2.59
- CELU $1.63
- Analyst Decision
- GWH Hold
- CELU
- Analyst Count
- GWH 5
- CELU 0
- Target Price
- GWH $3.35
- CELU N/A
- AVG Volume (30 Days)
- GWH 49.5K
- CELU 102.4K
- Earning Date
- GWH 03-31-2025
- CELU 12-06-2024
- Dividend Yield
- GWH N/A
- CELU N/A
- EPS Growth
- GWH N/A
- CELU N/A
- EPS
- GWH N/A
- CELU N/A
- Revenue
- GWH $6,295,000.00
- CELU $48,200,000.00
- Revenue This Year
- GWH $23.79
- CELU N/A
- Revenue Next Year
- GWH $331.34
- CELU $233.89
- P/E Ratio
- GWH N/A
- CELU N/A
- Revenue Growth
- GWH N/A
- CELU 225.94
- 52 Week Low
- GWH $2.51
- CELU $1.00
- 52 Week High
- GWH $14.10
- CELU $5.69
- Technical
- Relative Strength Index (RSI)
- GWH 30.06
- CELU 46.69
- Support Level
- GWH $3.20
- CELU $1.64
- Resistance Level
- GWH $3.55
- CELU $2.40
- Average True Range (ATR)
- GWH 0.27
- CELU 0.20
- MACD
- GWH 0.00
- CELU 0.01
- Stochastic Oscillator
- GWH 6.85
- CELU 17.20
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.